Under a tenth of individuals eligible to benefit from GLP-1 drugs such as Wegovy are able to get them, caution the World Health Organization as it issues its first advice on the drugs.
With in excess of 1,000,000,000 people worldwide currently obese, it is advocating for more widespread and fairer availability to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"The new guidance recognises that obesity is a lifelong illness that can be treated with holistic and lifelong care," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are major barriers to widespread availability to the treatments that can help people shift significant weight, explains the body.
Skinny Jab Shortage
Even under the present most favorable outlook, the manufacturing of these medications would only suffice for about 100 million people – fewer than 10% of eligible patients, as stated by the WHO.
The guideline calls on governments and firms to increase access, via strategies including patent sharing.
A patent on a key compound – the main component of a leading brand – is due to expire in multiple nations in 2026.
How Obesity Injections Operate
The injections mimick a body's own hormone to slow digestion, suppress the appetite and boost feelings of fullness so users eat less.
Individuals usually begin shedding pounds within a few weeks of starting on the weekly injections.
Studies suggests patients may put most of the weight back on a year later of halting the medication, as their typical hunger resume.
Being above a healthy weight increases your likelihood for contracting medical conditions, like diabetes, cardiovascular issues, brain attack, and some cancers.
Obesity concerns individuals in all nations and was associated with millions of fatalities worldwide in 2024, according to the health agency.
